Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
673 Results for "
K-Ras
" in MedChemExpress (MCE) Product Catalog:
Products (673)
673 Results for "K-Ras" in MCE Product Catalog:
Cat. No.: HY-175419
Synonyms: trans bis-Isatoic anhydride
Target:
Research Areas:
TBIA (trans bis-isatoic anhydride) is a covalent RNA crosslinker. TBIA selectively induces RNA tertiary interactions (e.g., multi-helix junctions, loop-helix packing). TBIA is promising for research of RNA higher-order structure and disease-associated RNAs (e.g., KRAS-mutant RNAs) .
Synonyms: (S)-JDQ-443; (S)-NVP-JDQ443
Target:
Research Areas:
(S)-Opnurasib ((S)-JDQ-443; (S)-NVP-JDQ443) is an isomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
Cat. No.: HY-139612B
CAS No.: 2653201-38-6
Synonyms: (Rac)-JDQ-443; (Rac)-NVP-JDQ443
Target:
Research Areas:
(Rac)-Opnurasib ((Rac)-JDQ-443; (Rac)-NVP-JDQ443) is the levorotomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50s between 0.25 and 0.76 μM) .
Cat. No.: HY-175575
CAS No.: 3027979-08-1
Research Areas:
SOS1 ligand-2 is a SOS1 ligand that can be used for PROTAC synthesis. SOS1 ligand-2 serves as the target protein ligand for PROTAC SOS1 degrader-4 (HY-153674). SOS1 ligand-2 is applicable to the research of KRAS-mutant cancers .
Target:
Cat. No.: HY-170326
CAS No.: 1207597-54-3
Research Areas:
Hsp90-in-35 is an inhibitor of Hsp90, with an IC50 between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize KRAS G12C degrader-1 (PROTAC) (HY-153881) .
Cat. No.: HY-176492
Research Areas:
E3 Ligase Ligand-linker Conjugate 193 is an E3 ligase ligand-linker conjugate that incorporates the VHL Ligase Ligand (HY-170353) and linker (HY-176491). E3 Ligase Ligand-linker Conjugate 193 can be used for synthesis of PROTAC pan-KRAS degrader-1 (HY-176489) .
Cat. No.: HY-W599085
CAS No.: 2839207-57-5
Target:
Research Areas:
tert-Butyl (6-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-((triisopropylsilyl)ethynyl)naphthalen-2-yl)carbamate is a pharmaceutical intermediate that can be used to synthesize a variety of active compounds, such as KRAS inhibitors .
Cat. No.: HY-L947
1,859 compounds
Built on druggable heterocyclic backbones with tunable electrophilic warheads (halogens, cyano groups), our electrophilic heterocyclic fragment library targets non-conserved cysteine/lysine residues and screens covalent ligands through an electrophile-first workflow. It generates high-quality dual-functional fragments for KRAS, BTK and other popular targets, supporting MS and DEL high-throughput screening to accelerate covalent drug lead discovery.
MCE Electrophilic Heterocyclic Fragment Library Built on druggable heterocyclic backbones with tunable electrophilic warheads (halogens, cyano groups), our electrophilic heterocyclic fragment library targets non-conserved cysteine/lysine residues and screens covalent ligands through an electrophile-first workflow. It generates high-quality dual-functional fragments for KRAS, BTK and other popular targets, supporting MS and DEL high-throughput screening to accelerate covalent drug lead discovery.
Cat. No.: HY-149607
CAS No.: 2802453-88-7
SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research .
Cat. No.: HY-153674
PROTAC SOS1 degrader-4 (Compound 10) is a PROTAC degrader that targets the SOS1 protein for degradation by recruiting cereblon. It degrades SOS1 in NCI-H358, A-427, SW-620, and DLD-1 cells and inhibits the proliferation of various KRAS-mutant tumor cells, making it a useful tool for cancer research .
Cat. No.: HY-173405
CAS No.: 3055319-82-6
VVD-699 is a covalent blocker of the RAS-p110α interaction with oral activity. VVD-699 inhibits activation of PI3Kα (IC50: 104 nM in H358 cells) . VVD-699 inhibits phosphorylated AKT. VVD-699 can be used for the research of KRAS mutant/amplified cancer .
Cat. No.: HY-181734
Research Areas:
E3 Ligase Ligand-linker Conjugate 224 is an E3 Ligase Ligand-Linker Conjugate that incorporates a ligand for VHL (HY-170348) and a PROTAC linker (HY-W895436). E3 Ligase Ligand-linker Conjugate 224 can be used for synthesis of KRAS G12D PROTAC degrader MS243 (HY-181728) .
Cat. No.: HY-182706
CAS No.: 95455-02-0
Target:
Research Areas:
NSC 373981 is a CARD11 G4 stabilizer. NSC 373981 stabilizes the CARD11 G4 structure and inhibits CARD11 transcription in cells. NSC 373981 also inhibits BCL2 and MYC. NSC 373981 suppresses the transcription of KRAS and TERT. NSC 373981 exhibits anticancer activity against diffuse large B-cell lymphoma .
Cat. No.: HY-163880
Target:
Research Areas:
EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential .
Cat. No.: HY-164427
CAS No.: 2411321-35-0
SHP2-IN-31 is a SHP2 inhibitor, with IC50s of 13 nM (Wild-type SHP2), >10000 nM (SHP1), >10000 nM (SHP2 E76K) . SHP2-IN-31 inhibits pERK in a panel of tumor cells. SHP2-IN-31 inhibits tumor growth in RTK/KRAS-driven xenograft models .
Cat. No.: HY-184902
CAS No.: 3110809-62-3
FAK-IN-32 is an orally active, selective and highly potent FAK inhibitor (IC50 = 10.87 nM). FAK-IN-32 can induce cell cycle arrest at the G2/M phase, inhibit FAK-AKT signaling pathway activity, and promote apoptosis to some extent. FAK-IN-32 can be used for research on KRAS-mutant colorectal cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
